<p>SH-SY5Y and CHP126 cells were seeded and treated with bortezomib (A) or ATRA (B) for 96 h, and Trypan blue staining was used to detect the surviving cells. Dose-response curves of the two cell lines treated with bortezomib (A) and ATRA (B) are presented. SH-SY5Y (C) and CHP126 (D) cells were treated as described above. The cell growth curves were created by counting cells each day. Massive cell death of SH-SY5Y and CHP126 cells was induced by treatments (E and F). Data are shown as the means ± SE (n = 3).BTZ = bortezomib.</p
<p>(A-B) Knock down of Atg3 mRNA and protein by siRNA was confirmed by qRT-PCR and Western blotting ...
PURPOSE: The proteasome inhibitor bortezomib inhibited cell growth and angiogenesis in neuroblast...
<p>A) REN and JU77 selected for resistance after exposure to increasing doses of bortezomib were tes...
<p>SH-SY5Y (A) and CHP126 (C) cells were treated with 5.0 nM bortezomib, 10.0 nM ATRA and 5.0 nM bor...
<p>A. Cells were incubated with 5.0 µM ATRA, 20.0 nM bortezomib, 5.0 nM bortezomib, 10.0 nM ATRA and...
<p>A: WB was used to detect the expression of pJNK, RARα, RARβ, pERK and pp38 after SP600125 treatme...
*<p>ATRA alone: Viability at 15 µM.</p><p>SH-SY5Y cells were pre-treated for 2 h with inhibitor (or ...
<p>(A). Frequency of apoptosis of RPMI 8226 and AMO1. Left panels: dot plots showing the frequency o...
<p>(A) Dose-response curve of bortezomib sensitivity in representative cell lines. The vertical axis...
Background: Bortezomib is a selective and reversible inhibitor of the 26S proteasome that shows pot...
<p>SH-SY5Y (A) and CHP126 (B) cells were incubated with 5 nM bortezomib, 10 nM ATRA and bortezomib p...
The proteasome inhibitor bortezomib (Velcade) was recently approved for the treatment of therapy-ref...
<p>(<b>a</b>) gIC<sub>50</sub> values observed for I-BET726 in a panel of neuroblastoma cell lines o...
<p>(A) Viability assay evaluated by trypan blue exclusion was performed in BC3 (left panel) and BCBL...
<p>(A) Viability of the cells treated with different concentrations of TRAIL or DR5-B during 8, 16, ...
<p>(A-B) Knock down of Atg3 mRNA and protein by siRNA was confirmed by qRT-PCR and Western blotting ...
PURPOSE: The proteasome inhibitor bortezomib inhibited cell growth and angiogenesis in neuroblast...
<p>A) REN and JU77 selected for resistance after exposure to increasing doses of bortezomib were tes...
<p>SH-SY5Y (A) and CHP126 (C) cells were treated with 5.0 nM bortezomib, 10.0 nM ATRA and 5.0 nM bor...
<p>A. Cells were incubated with 5.0 µM ATRA, 20.0 nM bortezomib, 5.0 nM bortezomib, 10.0 nM ATRA and...
<p>A: WB was used to detect the expression of pJNK, RARα, RARβ, pERK and pp38 after SP600125 treatme...
*<p>ATRA alone: Viability at 15 µM.</p><p>SH-SY5Y cells were pre-treated for 2 h with inhibitor (or ...
<p>(A). Frequency of apoptosis of RPMI 8226 and AMO1. Left panels: dot plots showing the frequency o...
<p>(A) Dose-response curve of bortezomib sensitivity in representative cell lines. The vertical axis...
Background: Bortezomib is a selective and reversible inhibitor of the 26S proteasome that shows pot...
<p>SH-SY5Y (A) and CHP126 (B) cells were incubated with 5 nM bortezomib, 10 nM ATRA and bortezomib p...
The proteasome inhibitor bortezomib (Velcade) was recently approved for the treatment of therapy-ref...
<p>(<b>a</b>) gIC<sub>50</sub> values observed for I-BET726 in a panel of neuroblastoma cell lines o...
<p>(A) Viability assay evaluated by trypan blue exclusion was performed in BC3 (left panel) and BCBL...
<p>(A) Viability of the cells treated with different concentrations of TRAIL or DR5-B during 8, 16, ...
<p>(A-B) Knock down of Atg3 mRNA and protein by siRNA was confirmed by qRT-PCR and Western blotting ...
PURPOSE: The proteasome inhibitor bortezomib inhibited cell growth and angiogenesis in neuroblast...
<p>A) REN and JU77 selected for resistance after exposure to increasing doses of bortezomib were tes...